Global Expansion Optimapharm has recently expanded its US footprint with a new Boston office to enhance customer collaboration, signaling growth initiatives and increasing potential for CRO partnerships across North America.

Leadership Strength With Ivana Waller as CEO and a growing senior leadership team,Optimapharm demonstrates active strategic execution and experienced governance, which can reassure sponsors seeking reliable, scale-ready clinical development partners.

Clinical Reach Operates in 40+ countries and claims twice the patient reach of the average mid-sized CRO, offering sponsors faster study start-up timelines and access to diverse patient populations for Phase I–IV trials.

Lifecycle Support Beyond regulatory approvals, the company emphasizes real-world evidence generation and lifecycle optimisation, presenting opportunities to position as a partner for post-approval studies, registries, and repositioning strategies.

Mid-Sized Advantage Revenue range ($100M–$250M) and 201–500 employees place Optimapharm in a sweet spot for sponsors seeking scalable, mid-market CROs with agility, cost efficiency, and personalized client engagement.